Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERFERON-ALPHA FOR INDUCTION AND MAINTENANCE IN MULTIPLE-MYELOMA - RESULTS OF 2 MULTICENTER RANDOMIZED TRIALS AND SUMMARY OF OTHER STUDIES
Autore:
LUDWIG H; COHEN AM; POLLIACK A; HUBER H; NACHBAUR D; SENN HJ; MORANT R; ECKHARDT S; GUNCZLER P; SEEWANN HL; SCHULLER J; RHYNER K; CAVALLI F; FRITZ E;
Indirizzi:
WILHELMINENSPITAL STADT WIEN,DEPT MED & ONCOL 1,MONTLEARTSTR 37 A-1171 VIENNA AUSTRIA HASHARON HOSP,GOLDA MED CTR,DEPT HEMATOL PETAH TIQWA ISRAEL HADASSAH MED CTR,DEPT HEMATOL IL-91120 JERUSALEM ISRAEL UNIV VIENNA,DEPT MED 1 VIENNA AUSTRIA INNSBRUCK UNIV,DEPT MED A-6020 INNSBRUCK AUSTRIA KANTONSSPITAL,DEPT MED ONCOL C ST GALLEN SWITZERLAND NATL INST ONCOL BUDAPEST HUNGARY AESCA TRAISKIRCHEN AUSTRIA LANDESKRANKENHAUS GRAZ,DEPT MED 3 GRAZ AUSTRIA RUDOLFSTIFTUNG,DEPT MED 1 VIENNA AUSTRIA UNIV ZURICH,MED POLIKLIN ZURICH SWITZERLAND OSPED SAN GIOVANNI BELLINZONA,DIV ONCOL BELLINZONA SWITZERLAND
Titolo Testata:
Annals of oncology
fascicolo: 5, volume: 6, anno: 1995,
pagine: 467 - 476
SICI:
0923-7534(1995)6:5<467:IFIAMI>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
PREVIOUSLY UNTREATED PATIENTS; HUMAN-LEUKOCYTE INTERFERON; MELPHALAN-PREDNISONE; CENTRAL-SWEDEN; CLINICAL-TRIAL; CHEMOTHERAPY; ALFA-2B; COMBINATION; LYMPHOMA; THERAPY;
Keywords:
INDUCTION THERAPY; INTERFERON-ALPHA; MAINTENANCE TREATMENT; METAANALYSIS; MULTIPLE MYELOMA; RANDOMIZED TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
44
Recensione:
Indirizzi per estratti:
Citazione:
H. Ludwig et al., "INTERFERON-ALPHA FOR INDUCTION AND MAINTENANCE IN MULTIPLE-MYELOMA - RESULTS OF 2 MULTICENTER RANDOMIZED TRIALS AND SUMMARY OF OTHER STUDIES", Annals of oncology, 6(5), 1995, pp. 467-476

Abstract

Background: Interferon (IFN) treatment trials in multiple myeloma have yielded discordant results regarding response rates, maintenance duration, and survival times. Further randomized trials and global evaluations of available data are urgently needed for clarification. Patients and methods: 256 patients participated in a randomized trial, 125 onIFN + VMCP, and 131 on VMCP alone. 100 patients were randomized to IFN maintenance (n=46) or were untreated controls (n=54). Global evaluations are based on 1,518 patients in induction and 924 in maintenance trials. Results: The induction trial demonstrated a significantly (p<0.05) lower rate of progressive disease under IFN + VMCP (10.6%) than under VMCP (22.9%), but this benefit was limited to stage I or II patients. Median progression-free survival was longer in the IFN + VMCP arm (23.2 months vs. 15.8 months); median overall survival did not differ significantly (38.9 vs. 30.2 months). The IFN maintenance treatment trial showed significantly superior results in the IFN arm versus controls (median maintenance duration: 17.8 months and 8.2 months (p<0.01), survival: 50.6 and 34.4 months (p<0.05), respectively). Previous IFN treatment increased the benefits of IFN maintenance therapy. Adverse effects of IFN during induction were hematologic toxicity, fever, and infections, requiring dose reductions. Toxic effects of IFN maintenance treatment were mild. Global evaluations of randomized trials showed small but significant benefits of combined IFN induction therapy and significantly prolonged maintenance duration and survival under IFN maintenance. Conclusions: Presently available data support the use of IFN maintenance treatment because it significantly prolongs maintenance duration and survival. IFN added to induction chemotherapy resulted in minor improvements at the expense of increased toxicity, highlighting the need for better induction regimens.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 16:00:14